Axsome Therapeutics (AXSM) received a Refusal to File letter by the FDA’s Division of Anesthesiology, Addiction Medicine, and Pain Medicine regarding AXS-14, with the division finding the new drug application to be incomplete given one of the two trials in Axsome’s regulatory filing used a flexible-dose schedule with an 8-week endpoint, Morgan Stanley analyst Vikram Purohit tells investors in a research note. An additional trial exploring a fixed-dose regimen with a 12-week primary endpoint will begin in Q4, the firm says. Morgan Stanley, which has an Overweight rating and $190 price target on the shares, continues to see the commercial trajectory of Auvelity in major depressive disorder and regulatory progress with AXS-05 in Alzheimer’s disease agitation as the key drivers of Axsome for 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics’ Growth Prospects Remain Strong Despite FDA Setback on AXS-14
- Axsome Therapeutics’ Strategic Response to FDA Feedback Supports Buy Rating
- FDA Refuses Axsome’s NDA for Fibromyalgia Drug
- Axsome Therapeutics receives RTF letter from FDA for AXS-14 NDA
- Axsome Therapeutics: A Promising Growth Stock with Robust Pipeline and Strong Financials